Aethlon Medical (AEMD) Q1 2025 earnings summary

Executive summary

• Achieved key milestones in advancing the Hemopurifier clinical program for oncology, with full ethics approvals at two Australian sites and preparations for additional sites in Australia and India underway.

• Focused on reducing expenses and progressing the oncology indication, with measurable results in both areas since November 2023.

• Closed a $4.7M public equity offering in May 2024, with additional warrant exercises raising $1.8M.

• Continued progress in oncology and infectious disease research, with ongoing COVID-19 trial in India and preclinical evidence supporting Hemopurifier's effectiveness.

Financial highlights

• Cash and equivalents at June 30, 2024 were $9.1 million, up from $5.44 million at March 31, 2024.

• Operating expenses for the quarter were $2.6 million, down 24% from $3.4 million in the prior year quarter, mainly due to lower general/admin expenses and professional fees.

• Net loss for Q2 2024 was $2.57 million, down from $3.3 million year-over-year.

• Weighted average shares outstanding increased to 7.5 million from 2.4 million year-over-year due to equity issuances.

• Excluding a $300,000 employee termination provision, operating expenses decreased by over $1 million quarter-over-quarter.

Outlook and guidance

• Management expects existing cash to fund operations for at least 12 months from the report date.

• Enrollment for the Australian oncology trial anticipated to open in mid- to late September or October 2024, with further site activations and international expansion (India) planned.

• Anticipates increased clinical trial and manufacturing expenses as oncology trials commence in Australia and India.

• Expect further reductions in professional fees due to changes in law and accounting firms.